Meetings/Workshops on Hepatology in the United States (USA)

Submit a meeting

Select a location:
Canada (1) - France (1) - Philippines (2) - Portugal (1) - Sweden (1) - United Arab Emirates (1) - United Kingdom (1) - United States (2) - ALL COUNTRIES (10)

2019 NASH-TAG Conference
03 Jan 2019 - 05 Jan 2019 • Park City, Utah, United States
The NASH-TAG Conference is designed to bring together clinicians and researchers in academia and the pharmaceutical industry for a focused interactive educational update highlighting the most relevant advances and challenges in the diagnosis and therapy of NASH and liver fibrosis. NASH-TAG 2019 will take place over two days providing attendees an understanding of current and future directions in diagnostic procedures, prospects and challenges in drug discovery and development for both NASH and liver fibrosis. Internationally renowned faculty will assist in the development of the educational content and will serve as faculty at the conference.
NASH, liver fibrosis, Therapeutic Agents, Non-alcoholic Steatohepatitis, diagnostic procedures, drug discovery, educational updates
Event listing ID:
Keystone Symposia: Integrated Pathways of Disease in NASH and NAFLD
20 Jan 2019 - 24 Jan 2019 • Santa Fe, New Mexico, United States
The global prevalence of nonalcoholic fatty liver disease (NAFLD) has risen precipitously over the past two decades in parallel with the worldwide obesity epidemic; however, there are no approved therapies. The more advanced form of the disease, non-alcoholic steatohepatitis (NASH), is associated with progressive fibrosis and an increased risk of liver cancer. Despite the growing number of systemic and liver-specific abnormalities identified in patients with NAFLD, a clear hierarchy of the relative importance of specific defects has not emerged. Furthermore, a clear understanding of which individuals are at highest risk for progression to advanced liver disease and cancer remains elusive. Thus, the field lacks an integrated understanding of risk prediction, pathogenesis and validated biomarkers to predict or track disease progression without reliance on liver biopsies. Therefore, the goals of this conference are to: 1) Explore genetic and ethnic contributions to NAFLD development; 2) Clarify underlying pathogenic defects in NAFLD and NASH, focusing on the specific contributions of lipotoxicity, the microbiome, innate immune signaling and drivers of fibrosis; and 3) Highlight emerging prognostic and diagnostic biomarkers that are yielding new, more streamlined clinical trial designs to evaluate novel therapies. As a result of this conference, attendees should gain a more holistic understanding of the unmet needs and new paths to advancing our understanding of NAFLD pathogenesis, diagnosis and therapy. The multidisciplinary nature of the topics and speakers promises to generate novel insights that represent convergent expertise and opinion. In doing so, new paradigms are likely to emerge that greatly inform the expanding number of emerging diagnostic markers and therapeutic agents. The conference comes at a propitious time when there is already sufficient basic translational and clinical research to extract important new insights, focus on unmet needs and refine research strategies for the future
Attendee Services;     Phone: [970.262.1230];     Email:
microbiome, hepatology, liver cancer, metabolic diseases
Event listing ID:

View all listed conferences in the United States (USA). offers, as part of its business activities, a directory of upcoming scientific and technical meetings. The calendar is published for the convenience of conference participants and we strive to support conference organisers who need to publish their upcoming events. Although great care is being taken to ensure the correctness of all entries, we cannot accept any liability that may arise from the presence, absence or incorrectness of any particular information on this website. Always check with the meeting organiser before making arrangements to participate in an event!

Last updated: 28 October 2018